Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-018-1632-9
Abstract: BackgroundThis post-marketing surveillance (PMS) study evaluated the safety and effectiveness of long-term darbepoetin alfa (darbepoetin) for the treatment of renal anemia in Japanese non-dialysis chronic kidney disease patients.MethodsPatients were treated with darbepoetin and followed up… read more here.
Keywords: long term; cardiovascular related; safety; safety effectiveness ... See more keywords
Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
Sign Up to like & getrecommendations! Published in 2021 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2021.07.015
Abstract: Introduction Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. Methods This 52-week, randomized, double-blinded,… read more here.
Keywords: receiving dialysis; japanese patients; molidustat; molidustat darbepoetin ... See more keywords
The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Veterinary Internal Medicine"
DOI: 10.1111/jvim.14681
Abstract: Background Darbepoetin alfa (darbepoetin) is an erythropoiesis‐stimulating agent used for the treatment of anemia secondary to chronic kidney disease (CKD) in dogs, but reports describing response are lacking. Hypothesis/Objectives To evaluate the effectiveness of darbepoetin… read more here.
Keywords: chronic kidney; treatment; treatment anemia; darbepoetin ... See more keywords
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of nephrology"
DOI: 10.1159/000518071
Abstract: INTRODUCTION Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat… read more here.
Keywords: anemia; treatment; efficacy; molidustat ... See more keywords
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0231830
Abstract: Renal anemia is predominantly caused by a relative deficiency in erythropoietin (EPO). Conventional treatment for renal anemia includes the use of recombinant human EPO (rhEPO) or a long-acting erythropoiesis-activating agent named darbepoetin alfa, which is… read more here.
Keywords: long acting; darbepoetin alfa; darbepoetin; erythropoiesis ... See more keywords
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2019060623
Abstract: BACKGROUND Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia.… read more here.
Keywords: study; darbepoetin alfa; ckd; darbepoetin ... See more keywords